Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Schuchat, K. Robinson, J.D. Wenger, L.H. Harrison, M. Farley, A.L. Reingold, et al.
Bacterial meningitis in the United States 1995.
N Engl J Med, 337 (1997), pp. 970-978
[2.]
J.A. Soult Rubio, C. Rangel Pineda, M. Muñoz Sáez, J.S. Parrilla Parrilla, F. Díaz Fernández, J.D. López Castilla, et al.
Meningitis neumocócica: características epidemiológicas, clínicas y bacteriológicas.
An Esp Pediatr, 55 (2001), pp. 315-320
[3.]
A. Kaul, S. Chandwani.
Dexamethasone in bacterial meningitis: To use or not to use?.
Indian J Pediatr, 63 (1996), pp. 583-589
[4.]
M.G. Tauber, B. Moser.
Cytoquines and chemoquines in meningeal infammation: Biology and clinical implications.
Clin Infect Dis, 28 (1999), pp. 1-11
[5.]
O. Hoffmann, N. Keilwerth, M.B. Bille, U. Reuter, K. Angstwurm, R.R. Schumann, et al.
Triptans reduce the inflammatory response in bacterial meningitis.
J Cereb Blood Flow Metab, 22 (2002), pp. 988-996
[6.]
S.L. Leib, D. Leppert, J. Clements, M. Tauber.
Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.
Infect Immun, 68 (2000), pp. 615-620
[7.]
S.L. Leib, J.M. Clements, R.L. Lindberg, C. Heimgartner, J.M. Loeffler, L.A. Pfister, et al.
Inhibition of matrix proteases and tumour necrosis factor alfa converting enzyme as adjuvant therapy in pneumococcal meningitis.
Brain, 124 (2001), pp. 1734-1742
[8.]
D.N. Meli, S. Christen, S.L. Leib, M.G. Tauber.
Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae.
Curr Opin Infect Dis, 15 (2002), pp. 253-257
[9.]
J.S. Braun, J.E. Sublett, D. Freyer, T.J. Mitchell, J.L. Cleveland, E.I. Tuomanen, et al.
Pneumococcal pneumolysin and H2O2 medate brain cell apoptosis during meningitis.
J Clin Invest, 109 (2002), pp. 19-27
[10.]
T. Bottcher, J. Gerber, A. Wellmer, A.V. Smirnov, F. Fakhrjanali, E. Mix, et al.
Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis.
J Infect Dis, 181 (2000), pp. 2095-2098
[11.]
C. Cabellos, J. Martínez-Lacasa, F. Tubau, A. Fernández, P.F. Viladrich, J. Linares, et al.
Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis.
J Antimicrob Chemother, 45 (2000), pp. 315-320
[12.]
J. Martínez-Lacasa, C. Cabellos, A. Martos, A. Fernández, F. Tubau, P.F. Viladrich, et al.
Experimental study on the efficacy of vancomycin, rifampin and dexamethasone in the therapy of pneumococcal meningitis.
J Antimicrob Chemother, 49 (2002), pp. 507-513
[13.]
J. De Gans, D. Van de Beeek.
European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis.
N Engl J Med, 347 (2002), pp. 1549-1556
[14.]
M.M. Paris, S.M. Hickey, M.I. Usher, S. Shelton, K.D. Olsen, G.H. Jr. McCracken.
Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin- resistant pneumococcal meningitis.
Antimicrob Agents Chemother, 38 (1994), pp. 1320-1324
[15.]
A. Martos, C. Cabellos, J. Martínez-Lacasa, P.F. Viladrich, F. Gudiol.
Protective effect of dexamethasone and phenytoin in the treatment of experimental pneumococcal meningitis.
Enferm Infec Microbiol Clin, 13 (1995), pp. 146-150
[16.]
S.C. Buckingham, J.A. McCullers, J. Lujan-Zilbermann, K.M. Knapp, K.L. Orman, B.K. English, et al.
Pneumococcal meningitis in children: Relationship of antibiotic resistance to clinical characteristics and outcomes.
Pediatr Infect Dis J, 20 (2001), pp. 837-843
[17.]
M. Auburtin, R. Porcher, F. Bruneel, A. Scanvic, J.L. Trouillet, J.P. Bedos, et al.
Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases.
Am J Respir Crit Care Med, 165 (2002), pp. 713-717
[18.]
A. Fernández, C. Cabellos, F. Tubau, J. Liñares, P.F. Viladrich, F. Gudiol, et al.
Relationship between penicillin and cephalosporin resistance of Streptococcus pneumoniae strains and its inflammatory activity in the experimental model of meningitis.
Med Microbial Immunol (Berl), 190 (2001), pp. 135-138
[19.]
P.F. Viladrich, C. Cabellos, R. Pallarés, F. Tubau, J. Martínez-Lacasa, J. Linares, et al.
High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.
Antimicrob Agents Chemother, 40 (1996), pp. 218-220
[20.]
J. Oteo, S. Cruchaga, J. Campos, J.A. Sáez-Nieto, F. Baquero, et al.
Miembros españoles del Grupo del EARSS. Resistencia a antibióticos en Streptococcus pneumoniae aislados de LCR y sangre en 33 hospitales españoles de la Red Europea de Vigilancia de Resistencia a antibióticos (2000).
Enf Infec Microbiol Clin, 20 (2002), pp. 12-19
[21.]
P. McMaster, P. McIntyre, R. Gilmour, L. Gilbert, A. Kakakios, S. Mellis.
The emergence of resistant pneumococcal meningitis –implications for empiric therapy.
Arch Dis Child, 87 (2002), pp. 207-210
[22.]
S.L. Kaplan.
Management of pneumococcal meningitis.
Pediatr Infect Dis J, 21 (2002), pp. 589-591
[23.]
X. Sáez-Llorens, M. O’Ryan.
Cefepime in the empiric treatment of meningitis in children.
Pediatr Infect Dis J, 20 (2001), pp. 356-361
[24.]
C.M. Odio, J.R. Puig, J.M. Feris, W.N. Khan, W.J. Rodríguez, G.H. Jr. McCracken, et al.
Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs cefotaxime therapy in bacterial meningitis in children.
Pediatr Infect Dis J, 18 (1999), pp. 581-590
[25.]
J.A. McCullers, B.K. English, R. Novak.
Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed meningitis.
J Infect Dis, 181 (2000), pp. 369-373
[26.]
I.R. Friedland, M. Paris, S. Ehrett, S. Hickey, K. Olsen, G.H. McCracken, et al.
Evaluation of antimicrobial regimens for treatment of experimental penicillinand cephalosporin-resistant pneumococcal meningitis.
Antimicrob Agents Chemother, 37 (1993), pp. 1630-1636
[27.]
X. Sáez-Llorens, C. McCoig, J.M. Feris, S.L. Vargas, K.P. Klugman, G.D. Hussey, et al.
Quinolone treatment for pediatric bacterial meningitis: A comparative study of trovafloxacin and ceftriaxone with or without vancomycin.
Pediatr Infect Dis J, 21 (2002), pp. 14-22
[28.]
G.H. Jr. McCracken.
Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
Clin Infect Dis, 31 (2000), pp. 45-50
[29.]
P. Cottagnoud, F. Acosta, M. Cottagnoud, M.G. Tauber.
Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.
Antimicrob Agents Chemother, 46 (2002), pp. 1607-1609
[30.]
P. Cottagnoud, F. Acosta, M. Cottagnoud, M. Pfister, M.G. Tauber.
Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis.
Antimicrob Agents Chemother, 46 (2002), pp. 184-187
[31.]
P. Cottagnoud, C.M. Gerber, F. Acosta, M. Cotagnoud, K. Neftel, M.G. Taub.
Linezolid against penicillin-sensitive and –resistant pneumococci in the rabbit meningitis model.
J Antimicrob Chemother, 46 (2000), pp. 981-985
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
